

EXECUTIVE SUMMARY

First Nine Months 2023




Main figures €Mn

Op. Revenue	EBITDA	EBIT
594.9 (+3%)	171.2 (-2%)	153.4 (-2%)
Net profit	Capex	Net debt
118.8 (-2%)	26.8 (+45%)	5.8


2024 operating revenue guidance:
Decrease by a mid-single-digit percentage vs 2023

- ✓ FDA approved ROVI's CDMO's injectable plants for the manufacture of Moderna's COVID-19 mRNA vaccine.
- ✓ On 21 September 2023, ROVI received the Establishment Inspection Report from the FDA from the inspection of the facility. The FDA has established a new Goal Date, the 29 March 2024.
- ✓ First place in the Sustainalytics world ESG risk ranking for the second year running.

Operating revenue €Mn



Specialty pharma business €Mn



Heparin franchise* €181.7 (-10%) 31% of operating revenue

LMWH €175.4 (-10%)

Bemiparin sales

€67.3m (-11%)

Spain €46.1m (-9%)

International €21.2m (-17%)

Enoxaparin sales

€108.1m (-9%)

- ✓ Directly marketed in Germany, UK, Italy, France, Belgium, Portugal, Spain, Poland and Austria.
- ✓ Launched in 40 countries.

- ✓ Approved in 26 countries in Europe and 33 in RoW.

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins


CDMO¹ business €Mn

Total €287.6m (+7%)


¹Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the first nine months of 2023. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>


Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn



R&D expenses €Mn €16.5

+2%

Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Approved	Approved in Europe and in approval process in USA
Letrozole ISM®, annual	Breast Cancer	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole LEBE, quarterly	Breast Cancer	Phase I	
Risperidone, quarterly	Schizophrenia	Phase I	


Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the first nine months of 2023. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>



Net profit €Mn



News flow

SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ New product distribution licenses
- ✓ Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

CDMO

- ✓ Evolution of Moderna's vaccine manufacturing.

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe (already launched in Germany, UK, Spain, Portugal and Italy)
- ✓ Marketing authorization for Risvan® in USA
- ✓ Phase I clinical development of a three-monthly formulation of letrozole (Letrozole LEBE)
- ✓ Phase I clinical development of Risperidone for a 3-monthly injection